Brevan Howard Capital Management LP Makes New Investment in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Brevan Howard Capital Management LP bought a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 9,804 shares of the specialty pharmaceutical company's stock, valued at approximately $281,000.

Other large investors also recently modified their holdings of the company. New Age Alpha Advisors LLC bought a new position in shares of Collegium Pharmaceutical in the fourth quarter valued at approximately $40,000. KBC Group NV increased its position in shares of Collegium Pharmaceutical by 72.5% during the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock valued at $67,000 after acquiring an additional 982 shares during the last quarter. Nisa Investment Advisors LLC increased its position in shares of Collegium Pharmaceutical by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock valued at $71,000 after acquiring an additional 316 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Collegium Pharmaceutical by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company's stock valued at $196,000 after acquiring an additional 642 shares during the last quarter. Finally, Aigen Investment Management LP purchased a new stake in shares of Collegium Pharmaceutical during the fourth quarter valued at approximately $230,000.

Insider Activity

In other news, EVP Shirley R. Kuhlmann sold 40,000 shares of Collegium Pharmaceutical stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the completion of the transaction, the executive vice president now directly owns 154,204 shares in the company, valued at approximately $4,330,048.32. The trade was a 20.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Colleen Tupper sold 977 shares of Collegium Pharmaceutical stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $29,310.00. Following the completion of the transaction, the chief financial officer now owns 164,269 shares of the company's stock, valued at approximately $4,928,070. This trade represents a 0.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 81,693 shares of company stock worth $2,334,994. 2.51% of the stock is owned by corporate insiders.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL traded up $0.89 during trading hours on Friday, reaching $30.23. The stock had a trading volume of 430,854 shares, compared to its average volume of 429,690. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The stock has a 50 day simple moving average of $28.12 and a 200 day simple moving average of $29.85. Collegium Pharmaceutical, Inc. has a 12-month low of $23.23 and a 12-month high of $42.29. The stock has a market cap of $971.35 million, a P/E ratio of 13.03 and a beta of 0.63.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.50 by ($0.01). Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The firm had revenue of $177.76 million during the quarter, compared to analysts' expectations of $174.96 million. During the same period in the prior year, the business earned $1.45 earnings per share. The business's quarterly revenue was up 22.7% compared to the same quarter last year. On average, research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Piper Sandler reaffirmed a "neutral" rating and set a $37.00 price target (up from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday, May 9th. StockNews.com downgraded Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Saturday, April 19th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $46.00 price target on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Collegium Pharmaceutical currently has a consensus rating of "Moderate Buy" and an average price target of $43.80.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.